International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 440-447 www.ijprajournal.com ISSN: 2456-4494

Comprehensive Overview of Cleaning-In-Place (CIP) Systems and Their Validation in Pharmaceutical Manufacturing

Kiran Deokate[1*], Shrikrishna Baokar[2], Rajendra Patil[3]

[1]*Department of Pharmaceutical Quality Assurance, Delonix Society's Baramati Collage of Pharmacy, Barhanpur, Tal- Baramati, Dist- Pune, Maharashtra, India 413102*

[2]*Department of Pharmaceutical Analysis, Delonix Society's Baramati Collage of Pharmacy, Barhanpur, Tal- Baramati, Dist- Pune, Maharashtra, India 413102*

[3]*Department of Pharmaceutical Chemistry, Delonix Society's Baramati Collage of Pharmacy, Barhanpur, Tal- Baramati, Dist- Pune, Maharastra, India 413102*

Date of Submission: 20-07-2025 Date of Acceptance: 30-07-2025

ABSTRACT:
Cleaning-In-Place (CIP) is an essential process in the pharmaceutical, food, and beverage industries, ensuring the hygienic integrity of manufacturing equipment without the need for disassembly. This manuscript provides a detailed exploration of CIP systems, their evolution, and their application in maintaining product quality and safety. Special emphasis is placed on the validation of CIP processes to ensure their consistency and effectiveness in preventing cross-contamination and regulatory non-compliance. The document also explores protocol development, analytical testing, and continuous monitoring techniques to verify cleaning effectiveness. Ultimately, CIP validation promotes cost reduction, sustainability, and optimized process efficiency, supporting patient safety and regulatory adherence.

I. INTRODUCTION:(1-5)

In the contemporary landscape of pharmaceutical and biotechnological manufacturing, the importance of maintaining hygiene, sterility, and cross-contamination control cannot be overstated. High product quality, patient safety, and regulatory compliance are paramount, especially when dealing with sterile formulations, active pharmaceutical ingredients (APIs), and biologics. In this regard, Cleaning-In-Place (CIP) systems have emerged as a cornerstone technology that enables the internal cleaning of process equipment such as tanks, piping, filters, and reactors without the need for disassembly or manual intervention. (1)

Cleaning-in-place refers to an automated cleaning process that involves the circulation of cleaning solutions—usually under pressure and controlled conditions—through the production line's internal surfaces. This eliminates the need for labor-intensive, time-consuming manual cleaning and significantly reduces the risk of operator-induced variability and contamination. The adoption of CIP ensures that the equipment used in the manufacturing process remains free of residual materials from previous production runs, thereby preventing contamination and ensuring the integrity of each new batch.

The concept of CIP dates back to the mid-20th century when it was primarily used in the dairy and beverage industries. Over the decades, it has evolved considerably, now incorporating sophisticated elements such as programmable logic controllers (PLCs), automated valves, flow and temperature sensors, and real-time data logging systems. These developments have enabled more reliable, repeatable, and verifiable cleaning processes. Today's CIP systems are integral components of pharmaceutical manufacturing facilities, especially in large-scale production plants that demand high equipment utilization, quick product changeovers, and adherence to Good Manufacturing Practices (GMP).

Pharmaceutical manufacturing processes involve strict regulatory oversight, and cleaning validation has become a central requirement in ensuring that residual product, cleaning agent, microbial contamination, and other impurities are removed to acceptable levels. Regulatory authorities such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and World Health Organization (WHO) have issued clear guidelines that mandate manufacturers to demonstrate the effectiveness of their cleaning procedures through scientifically justified and well-documented validation protocols. In this context, CIP systems, when validated properly, offer a robust and standardized method of ensuring equipment cleanliness, which is critical for product safety, efficacy, and compliance.(2)

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 440-447 www.ijprajournal.com ISSN: 2456-4494

CIP systems also align with lean manufacturing and continuous improvement principles. Their use reduces downtime associated with manual cleaning, supports faster product changeovers, and contributes to operational efficiency. Additionally, with increasing global awareness of environmental sustainability, the pharmaceutical industry is embracing green CIP practices, such as reducing water and solvent consumption, recycling cleaning solutions, and using biodegradable cleaning agents.

One of the key advantages of CIP is its reproducibility. Once validated, CIP cycles can be consistently executed with minimal variability, and each cycle can be monitored and recorded for traceability. Furthermore, CIP allows cleaning of complex equipment geometries that would otherwise be difficult to clean manually, ensuring that even the most inaccessible surfaces meet cleanliness criteria. This is particularly important in the production of parenteral and sterile dosage forms, where the tolerance for contamination is extremely low.

The design of an effective CIP system is both a science and an engineering challenge. It involves the optimization of variables such as flow rate, temperature, chemical concentration, contact time, and mechanical action. The process must be robust enough to handle various types of product residues—whether sticky, insoluble, or sensitive to degradation—while avoiding overuse of resources or equipment damage. Consequently, cleaning process development and validation are closely tied to risk assessment, equipment design, product characteristics, and analytical capabilities. (3)

This review article aims to provide a comprehensive overview of CIP systems, focusing on their design, operational mechanisms, and validation approaches specific to the pharmaceutical sector. It also highlights best practices, recent technological advancements, regulatory expectations, and future directions in cleaning validation. Readers will gain a clear understanding of how to design, implement, and maintain a validated CIP program that not only ensures compliance and safety but also promotes operational excellence and sustainability.

Establishment of CIP Procedures: (6-8)

The successful implementation of a Cleaning-In-Place (CIP) system hinges upon the meticulous establishment of procedures that are both scientifically justified and compliant with current regulatory standards. The primary objective of establishing these procedures is to provide a validated, repeatable method for ensuring that equipment surfaces in contact with pharmaceutical products are consistently cleaned to a level that ensures product integrity and patient safety. Furthermore, CIP procedures must be flexible enough to accommodate different product residues, equipment designs, and manufacturing schedules, all while minimizing resource consumption and optimizing throughput.

The development of effective CIP procedures begins with a risk-based approach that considers the characteristics of the drug product, the nature of process residues, the complexity of equipment design, and the cleaning agents being used. This approach aligns with the International Conference on Harmonisation (ICH) Q9 guidelines on Quality Risk Management, which emphasize the identification and control of risks throughout the lifecycle of pharmaceutical processes.

A scientifically sound CIP procedure incorporates key design elements that ensure mechanical, thermal, and chemical action work synergistically to remove residues from equipment surfaces. The following principles are fundamental to the design and establishment of effective CIP procedures:

1. Highly Turbulent Flow

Turbulent flow is crucial to the mechanical cleaning action in CIP processes. Turbulence enhances the shear forces acting on equipment surfaces, thereby dislodging product residues, biofilms, and other contaminants that may not be removed through laminar flow or simple rinsing. It also promotes better mixing of cleaning agents and improves contact with all internal surfaces.

The Reynolds number (Re) is used to characterize flow regimes. For turbulent flow in piping systems, an Re > 4,000 is typically targeted. A minimum fluid velocity of 1.5 meters per second (m/s) is recommended to ensure adequate turbulence. However, depending on the viscosity of the residue and pipe diameter, higher velocities may be required.

Engineering simulations and flow modeling tools such as Computational Fluid Dynamics (CFD) are increasingly being used during the CIP system design phase to predict flow behavior and optimize flow patterns in complex equipment configurations. These tools help identify potential "dead legs" and areas of low flow where

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 440-447 www.ijprajournal.com ISSN: 2456-4494

residues might accumulate, ensuring design robustness from the outset.

2. High-Flow Cleaning Solution

An optimal flow rate is essential not just for turbulence but also for ensuring that the cleaning solution adequately wets all internal surfaces of the equipment. Insufficient flow can lead to poor cleaning efficacy, particularly in large or complex vessels, filters, and piping systems. Conversely, overly aggressive flow may cause equipment wear or splashing, leading to inefficient cleaning and potential safety risks.

Flow rates must be established during the design qualification (DQ) phase and verified during operational qualification (OQ) and performance qualification (PQ) phases of CIP validation. Flow meters and control valves are integrated into modern CIP skids to maintain precise flow rates during each phase of the cleaning cycle (pre-rinse, detergent wash, post-rinse, and final rinse).

The cleaning solution's flow rate must also be balanced with other parameters such as temperature, pressure, and chemical concentration to achieve the desired cleaning outcome without damaging the equipment or using excess utilities.

3. Spray Coverage and Impingement

Effective cleaning of tanks and large vessels often requires the use of spray devices, such as static spray balls, dynamic rotary spray heads, or jet nozzles. These devices are designed to distribute the cleaning fluid evenly over the entire internal surface area of the equipment.

Spray coverage ensures that the cleaning solution makes direct contact with all surfaces, including those in hard-to-reach corners and complex geometries. Two types of spray mechanisms are typically employed:

Low-Energy Wetting Action: Achieved by static spray balls that gently rinse surfaces, primarily used during initial rinsing steps.

High-Energy Impingement: Delivered through rotating or jetting spray devices that apply mechanical force to break down residues. These are particularly useful for cleaning dried-on, viscous, or adhesive product residues.

Spray ball coverage testing, often performed using riboflavin-based validation under UV light, is a widely accepted method to visually confirm complete surface coverage. This test helps identify shadow areas or blind spots where cleaning solution may not reach, guiding corrective measures such as repositioning nozzles or redesigning vessel geometry.

Advanced spray devices can also include self-cleaning features, which prevent clogging and ensure consistent performance across multiple CIP cycles. The selection of the appropriate spray device depends on the type of soil to be removed, tank volume, spray angle, and cleaning solution properties.

Integration of Key Design Elements (9)

While each of the above principles plays a distinct role in cleaning effectiveness, their combined effect determines the overall success of a CIP procedure. Therefore, a holistic approach that integrates fluid dynamics, equipment geometry, chemical kinetics, and cleaning sequence design is essential. This involves not only the physical design of the CIP system but also the development of cleaning cycles that are tailored to specific production needs.

Typical CIP cycles include the following phases:

- Pre-rinse: Removes gross contamination using water or a mild solution
- Detergent Wash: Applies chemical agents for residue breakdown
- Intermediate Rinse: Flushes away loosened debris and detergent
- Sanitization (optional): Uses steam or chemical sanitizers
- Final Rinse: Ensures complete removal of cleaning agents

Each phase must be validated with appropriate acceptance criteria, including residue limits, pH neutrality, conductivity, and microbial limits, as per product and regulatory requirements.

Factors Affecting Cleaning Efficiency:

Several parameters directly influence CIP effectiveness:

- **Temperature of the Cleaning Solution:** Higher temperatures increase molecular activity, enhancing the ability of cleaning agents to dissolve and remove residues. Optimal temperatures vary depending on the cleaning agent and soil type but typically range between 60–80°C [4].
- **Concentration of Cleaning Agent:** A higher concentration provides more active molecules to interact with contaminants, improving the overall cleaning power. However, excessively high concentrations may cause surface

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 440-447 www.ijprajournal.com ISSN: 2456-4494

degradation or safety hazards and must be optimized [4].

- **Contact Time:** Longer exposure allows the cleaning agent to break down stubborn residues effectively. The ideal contact time is determined during validation studies, ensuring sufficient time for chemical reactions without overuse of resources [4].

Validation of CIP Systems: (10-14)

Validation of Cleaning-In-Place (CIP) systems is a critical requirement in pharmaceutical manufacturing and is directly linked to the assurance of product safety, quality, and compliance with global regulatory standards. Validation provides documented evidence that the CIP process consistently and effectively removes residues—including product remnants, microbial contaminants, and cleaning agents—from process equipment surfaces to levels deemed acceptable based on toxicological, microbiological, and chemical safety considerations.(5)

Regulatory authorities such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), and PIC/S guidelines mandate that cleaning procedures be validated using a lifecycle approach. The International Society for Pharmaceutical Engineering (ISPE) and ICH Q8, Q9, and Q10 also emphasize science- and risk-based approaches to process validation, which includes cleaning operations as a critical quality assurance activity.

Protocol Development:

Validation starts with a well-defined protocol outlining:

- Cleaning agents to be used
- Operating conditions (temperature, flow rate, time)
- Sampling methods
- Analytical techniques
- Acceptance criteria

Each step is based on product characteristics, equipment design, and risk assessments to ensure thorough and compliant cleaning [6].

Worst-Case Scenario Selection:

Worst-case conditions are identified to challenge the cleaning process under the most difficult situations, such as:

- Products with poor solubility
- Equipment with hard-to-reach surfaces
- Shortened cleaning cycles

This approach ensures the process is robust enough for all production cases [6].

Sampling and Testing Plan: (15,16)

Sampling and testing form the backbone of cleaning validation and verification in Cleaning-In-Place (CIP) systems. The ultimate goal of the sampling plan is to provide quantitative and qualitative evidence that all residues—including APIs, excipients, microbial contaminants, and cleaning agents—have been effectively removed from product-contact surfaces. For any cleaning process to be validated, the selection of appropriate sampling locations and techniques, followed by accurate and sensitive analytical testing, is critical to ensure patient safety and regulatory compliance. (7)

Acceptance Criteria:

These criteria are based on toxicological evaluations and include:

- Maximum allowable carryover (MACO)
- Therapeutic daily dose
- Safety factors for worst-case exposure

Criteria must align with regulatory expectations and ensure patient safety [7].

Process Validation Steps (17-19)

Process validation is the cornerstone of demonstrating that a Cleaning-In-Place (CIP) system consistently delivers the intended cleaning performance under actual manufacturing conditions. Cleaning validation is not a one-time event; it involves a structured and systematic approach built upon sound scientific principles, risk-based evaluation, and regulatory compliance. The ultimate goal is to confirm that the cleaning procedures are capable of consistently removing residues to levels that do not pose a risk to product quality or patient safety.

In the pharmaceutical industry, validation is performed in accordance with guidelines such as FDA's Guidance for Industry on Process Validation (2011), EU Annex 15, and ISPE's Cleaning Validation Guidelines, which emphasize the use of a three-stage validation lifecycle model**:**

- Process Design
- Process Qualification
- Continued Process Verification

The qualification phase typically includes three consecutive successful cleaning validation runs under normal operating conditions, which

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 440-447 www.ijprajournal.com ISSN: 2456-4494

must consistently meet predefined acceptance criteria.

Activities Performed During Validation Runs

Each of the three validation runs includes the following essential steps:

- Adherence to SOPs: All cleaning activities must be performed exactly according to the established and approved Standard Operating Procedures (SOPs). Any deviation must be documented, investigated, and resolved.
- Verification of Critical Parameters: Parameters such as cleaning solution concentration, temperature, flow rate, spray coverage, and contact time are monitored in real-time using calibrated instruments and automation software. These parameters must stay within validated ranges.
- Visual Inspections: Equipment surfaces are inspected under defined lighting conditions to ensure there are no visible residues, discoloration, or surface irregularities.
- Sampling and Analytical Testing: Swab and rinse samples are collected from worst-case locations and analyzed using validated methods such as HPLC, TOC, or UV-spectroscopy.
- Comparison against Acceptance Criteria: Analytical data are compared against predefined limits based on toxicological calculations, daily dose, and safety factors. If all acceptance criteria are met, the process is considered validated.
- Lock-in of the Validated Process: Once validated, the process is locked in and transferred to routine operation. Any changes thereafter (equipment modification, product change, cleaning agent alteration) must be assessed for revalidation.

Continuous Monitoring

Cleaning validation does not end after the initial three runs. To maintain the validated state, Continued Process Verification (CPV) or Periodic Requalification is essential. This is especially critical for detecting process drifts, environmental influences, or wear-and-tear of equipment that may impact cleaning performance over time.

Key activities include:

- Routine Sampling: Periodic sampling of rinse or swab points helps confirm ongoing cleaning effectiveness.
- Review of Cleaning Logs: Detailed documentation of every cleaning cycle, including date, time, operator, equipment ID, parameters, and deviations, must be maintained.
- Trending and Statistical Analysis: Results from routine monitoring are trended using control charts, Pareto analyses, and process capability studies to identify gradual shifts, recurring issues, or declining performance.
- Trigger-based Revalidation: Revalidation is mandatory when there are changes in product formulation, cleaning agent, equipment design, production scale, or cleaning parameters.

Testing for Residuals

Testing for residuals is the most critical aspect of CIP validation. It ensures that the equipment is free from harmful or interfering materials before the next production batch begins.

Common types of tests include:

- Residue Testing: Using validated analytical methods (e.g., HPLC for API residues or TOC for general organic residues), this confirms that residues are below Maximum Allowable Carryover (MACO) limits.
- Spray Ball Coverage Studies: Performed during system design or qualification, spray ball efficiency is verified using riboflavin solution or fluorescent dyes under UV light to confirm total surface wetting. Incomplete spray patterns signal potential risks.
- Washout Curve Analysis: This involves plotting the concentration of a target residue in rinse water over time. A sharp decrease and plateau indicate effective removal.
- Detergent Residue Testing: Specialized tests (e.g., conductivity, titration, or specific assays) ensure that cleaning agents themselves are adequately rinsed out to avoid interference with the next product.
- Microbiological Testing: For sterile or aseptic processes, swab or rinse samples are plated to test for total viable count (TVC) or endotoxins (via LAL assay). Sterile equipment must meet zero microbial count criteria post-cleaning.

Effectiveness and Optimization of CIP Validation

A CIP process is considered effective when:

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 440-447 www.ijprajournal.com ISSN: 2456-4494

- Cleaning Results Are Reproducible: Repeated cycles yield consistent results under routine production conditions.
- Cross-contamination Risk Is Minimized: Proper cleaning prevents carryover between batches of different products.
- Cycle Times Are Optimized: Cleaning duration, temperature, and chemical use are fine-tuned to reduce downtime without compromising effectiveness.
- Cleaning Verification Is Integrated into QA: A robust Quality Management System (QMS) ensures documentation, deviation handling, and continuous improvement.

Optimization further involves:

- Using Design of Experiments (DoE): To evaluate the influence of process variables (e.g., time, temperature, concentration) on cleaning efficacy.
- Automated CIP Skids: Use PLCs, sensors, and SCADA systems to reduce variability and record all cycle parameters.
- Real-time Monitoring Tools: Conductivity, turbidity, and TOC sensors can be used in-line to monitor rinse water cleanliness.

Cost Reduction and Operational Benefits

Validated CIP systems can result in significant cost savings and operational efficiencies:

- Water and Energy Conservation: Optimized cycles use only the required amount of resources.
- Chemical Economy: Accurate dosing and reuse (where feasible) reduce chemical expenditure.
- Reduced Downtime: Faster and more effective cleaning translates into more production time.
- Less Manpower: Automation reduces manual labor and training costs.

According to recent ISPE benchmarking reports, properly validated CIP systems can reduce cleaning cycle time by up to 40%, directly impacting batch turnover and facility throughput.

Sustainability and Environmental Considerations (20, 21)

In modern pharmaceutical manufacturing, sustainability is not just a regulatory expectation but a corporate responsibility. CIP contributes to this goal through:

- Use of Biodegradable and Low-Toxicity Cleaning Agents: These reduce environmental burden during effluent treatment.
- Cleaning Solution Reuse: In multi-tank or multi-use systems, final rinse water from one vessel can serve as pre-rinse for another, minimizing wastewater generation.
- Minimized Emissions and Waste: Closed-loop CIP systems reduce exposure, evaporation losses, and spillages.

Furthermore, some companies are integrating Life Cycle Assessment (LCA) and Green Chemistry principles into CIP design to evaluate and mitigate the carbon and water footprints of their cleaning operations.

Industry Relevance and Application Areas

The principles of CIP validation are not confined to pharmaceuticals alone. Industries where hygiene and product purity are mission-critical all rely on validated CIP systems, including:

- Pharmaceutical Industry: Ensures product quality, eliminates cross-contamination, and complies with global regulatory standards.
- Food and Beverage Sector: Prevents allergen and flavor contamination, and supports food safety standards such as HACCP and ISO 22000.
- Biotechnology and Biologics: Critical in upstream (fermentation) and downstream (purification) processes, where even trace residues can cause process deviations or product degradation.
- Cosmetic and Personal Care Products: Ensures product integrity and consumer safety by eliminating colorants, perfumes, or actives from prior runs.

II. CONCLUSION:

The implementation and rigorous validation of Cleaning-In-Place (CIP) systems are essential to the safe and efficient operation of modern manufacturing environments, particularly in sectors such as pharmaceuticals, biotechnology, food processing, cosmetics, and nutraceutical, where product purity, hygiene, and cross-contamination control are critical to consumer safety and regulatory compliance.

Validated CIP systems ensure that residues from previous production cycles—including active pharmaceutical ingredients (APIs), excipients, microbial contaminants, and cleaning

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 4 July-Aug 2025, pp: 440-447 www.ijprajournal.com ISSN: 2456-4494

agents—are removed from equipment surfaces to levels well below defined safety thresholds. These thresholds are determined based on toxicological data, analytical sensitivity, and regulatory guidelines such as those from the U.S. FDA, EMA, ICH Q7, and WHO GMP standards. The result is not only compliance but also the assurance of patient safety and product efficacy.

CIP systems are no longer viewed merely as mechanical or operational installations. In the context of contemporary quality assurance frameworks, they represent integrated tools of risk control, process integrity, and regulatory compliance. Their automation enables uniformity, traceability, and real-time monitoring, thereby reducing human variability, manual errors, and inconsistencies across cleaning cycles. Sophisticated features like programmable logic controllers (PLCs), flow/pressure sensors, SCADA systems, and real-time TOC monitors offer enhanced visibility and control over the cleaning process, fulfilling both cGMP and 21 CFR Part

11 data integrity requirements.

The validation of CIP systems is not a static, one-time task. It involves a lifecycle approach encompassing:

- Process Design and Development
- Installation and Operational Qualification
- Performance Qualification
- Routine Verification and Revalidation

Such a structured approach ensures that cleaning remains effective throughout equipment life, despite changes in products, cleaning agents, process parameters, or equipment configuration.

A well-validated CIP program also contributes significantly to operational excellence. By optimizing parameters such as cleaning cycle duration, chemical concentration, flow velocity, and water usage, manufacturers can reduce:

- Batch changeover times
- Downtime
- Water and energy consumption
- Detergent costs
- Environmental impact

Moreover, validated CIP systems support sustainability and green manufacturing goals. Reuse of final rinse water, use of biodegradable or enzymatic cleaning agents, reduction in effluent loads, and decreased carbon and water footprints demonstrate corporate responsibility and align with ESG (Environmental, Social, and Governance) initiatives.

From a strategic perspective, robust CIP validation strengthens the quality culture of the organization. It builds confidence among regulators, customers, and internal stakeholders by demonstrating proactive risk management, documented control, and scientific rigor. In global markets with rising expectations for clean-label products, allergen control, and antimicrobial resistance mitigation, validated CIP systems also serve as competitive differentiators.

In conclusion, CIP systems are indispensable components of modern manufacturing architecture. When designed thoughtfully and validated rigorously, they enhance not only product quality and compliance but also drive efficiency, sustainability, and long-term profitability. As the industry continues to evolve towards continuous manufacturing, real-time release testing, and Industry 4.0 paradigms, the role of intelligent, adaptive, and validated CIP systems will become even more prominent. Regular review, revalidation, and innovation in cleaning technologies are thus essential to maintain the reliability, regulatory alignment, and effectiveness of these systems well into the future.

REFERENCES:

[1]. Rathore AS, Sofer G. Process validation in manufacturing of biopharmaceuticals. CRC Press; 2005.
[2]. Tim Sandle. Pharmaceutical Microbiology: Essentials for Quality Assurance and Quality Control. Elsevier; 2015.
[3]. Agalloco J, Carleton FJ. Validation of pharmaceutical processes. 3rd ed. CRC Press; 2007.
[4]. Swartz ME. Analytical Method Development and Validation. CRC Press; 2012.
[5]. ISPE. Cleaning Validation: Lifecycle Approach. ISPE Baseline Guide; 2016.
[6]. Fourie P. Practical Guide to CIP System Design and Validation. PharmaTech; 2017.
[7]. FDA. Guidance for Industry: Cleaning Validation. U.S. Food and Drug Administration; 2006.
[8]. Sundaram S. Principles of Clean-In-Place System Design. Bioprocess International; 2011.
[9]. Zief M, McClellan H. Pharmaceutical Cleaning Validation Techniques. Pharm Eng. 2013;33(6):20-32.

[10]. EMA. Guideline on setting health-based exposure limits. European Medicines Agency; 2018.
[11]. Viswanathan CT. Quality Assurance Practices for Pharmaceuticals. Springer; 2019.
[12]. Allmendinger A, Degen S. Lifecycle approach to cleaning validation: Application of science- and risk-based principles. J Pharm Sci. 2020;109(1):947–956. https://doi.org/10.1016/j.xphs.2019.12.011
[13]. Shah H, Gokhale R. Advances in analytical techniques for cleaning validation. J Pharm Innov. 2021;16:270–282. https://doi.org/10.1007/s12247-021-09517-4
[14]. Basu PK, Parmar M. Use of TOC analysis in cleaning validation: Challenges and solutions. PharmaTimes. 2022;54(8):18–23.
[15]. International Society for Pharmaceutical Engineering (ISPE). Cleaning Validation: Risk-Based Lifecycle Management Guide. ISPE; 2021.
[16]. Hussain A, Yu LX, Johnson JF. Quality by Design: Understanding and controlling cleaning processes. AAPS J. 2020;22(4):83. https://doi.org/10.1208/s12248-020-00453-8
[17]. Rawlings B. Green cleaning in pharmaceutical manufacturing. Cleanroom Technology. 2019;26(3):16–20.
[18]. Singh R, Wadhwa G. Design and automation of CIP systems for efficiency and sustainability. J Pharm Technol. 2021;45(2):85–91.
[19]. Hartman R, White D. Leveraging PAT and real-time monitoring in CIP systems. Pharm Eng. 2023;43(1):22–30.
[20]. World Health Organization (WHO). Technical Report Series No. 1025: Annex 7: GMP for cleaning of equipment. Geneva: WHO; 2021.
[21]. Chatterjee S, Bhowmik S. Impact of cleaning validation on cross-contamination control in multiproduct facilities. J Pharm QualAssur. 2022;3(1):43–51.